Active not recruiting
A Study of LY3023414 in Participants With Advanced Cancer
I6A-MC-CBBA - ClinicalTrials.gov - NCT01655225
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have.
How long will I be in the trial?
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Active not recruiting
A Study of LY3023414 in Participants With Advanced Cancer
I6A-MC-CBBA - ClinicalTrials.gov - NCT01655225
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have.
How long will I be in the trial?
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant in Part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy
Participant in Part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway
Participant in Part B7 must have HR+ abd HER2- breast cancer
Participant may need to undergo a biopsy dependent upon which arm of the study you are in
Participant must be able to swallow capsules
Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures
Participants must NOT
Participant must not have known acute or chronic leukemia
Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus
Trial Summary
Conditions the trial is for
Advanced Cancer, Mesothelioma, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkin's Lymphoma
What the trial is testing?
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Could I receive a Placebo?
no
Enrollment Goal
164
Trial Dates
July 2012 - February 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant in Part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy
Participant in Part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway
Participant in Part B7 must have HR+ abd HER2- breast cancer
Participant may need to undergo a biopsy dependent upon which arm of the study you are in
Participant must be able to swallow capsules
Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures
Participants must NOT
Participant must not have known acute or chronic leukemia
Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus
Trial Summary
Conditions the trial is for
Advanced Cancer, Mesothelioma, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkin's Lymphoma
What the trial is testing?
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Could I receive a Placebo?
no
Enrollment Goal
164
Trial Dates
July 2012 - February 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
